Company
ActiveSynchron
Melbourne, then New York · Since 2012
Still a clinical company. Its device is delivered through blood vessels, without open brain surgery.
A later timeline chapter projects a role for this organization. That chapter is a projection. This page is about the institution as it exists, or as it existed.
Synchron was founded in Australia in 2012 by Thomas Oxley and colleagues. Its device, a stentrode, is delivered through blood vessels and sits inside a vein over the motor cortex. The point of the route is to avoid opening the skull.
The company has run clinical studies aimed at letting people with paralysis control a computer. It is a medical employer, in Melbourne and New York, not a consumer brand. The 2040 chapter names it because it is the other real company in a field the press often reduces to one.
Closer to cardiology than to a headset
The procedure uses skills interventional neurologists and cardiologists already have. Synchron's staff design the implant and the decoder. The hands in the room belong to a hospital. That division, a small device firm and a large clinical workforce it does not employ, is how implants actually reach a patient. A projection that forgets the hospital has forgotten the payroll.
Early, and specific
Synchron is still a private clinical company. Its existence does not mean a worker will be asked to wear an interface. It means a group of people are already paid to solve a narrower problem, communication for someone who cannot move, with a method a regulator can evaluate. The page stops there on purpose.
The work it organized
- Neural engineer
- Clinical researcher
- Decoder scientist
- Regulatory lead